Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders.
Med Sci Monit
; 27: e934267, 2021 Nov 25.
Article
in English
| MEDLINE | ID: covidwho-1534578
ABSTRACT
BACKGROUND The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic diseases. Patients with rheumatologic diseases are usually on long-term corticosteroids and immunosuppressive therapy, which increases their risk for progressing to more severe forms of COVID-19. We report a case series of 4 patients with rheumatologic diseases who were treated with MAT for COVID-19. MATERIAL AND METHODS A retrospective observational study was conducted in our institution on patients with underlying rheumatological disorders who received MAT as per the EUA protocol of the FDA. RESULTS Two of the 4 patients were on immunosuppresive therapy at the time of receiving MAT. They recovered from COVID-19 without any adverse outcomes. No flare of underlying rheumatologic disease was noted. CONCLUSIONS MAT was observed to be a safe and effective therapy in 4 patients with rheumatological illnesses and COVID-19 treated at our hospital.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antibodies, Monoclonal, Humanized
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Immunotherapy
Type of study:
Case report
/
Observational study
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Language:
English
Journal:
Med Sci Monit
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Msm.934267
Similar
MEDLINE
...
LILACS
LIS